| Outcome Measures: |
Primary: Number of Participants With Acute Kidney Injury During the First 48 Hours After Contrast Administration, Contrast-Associated Acute Kidney Injury, defined as the increase of serum creatinine \>0.3 mg/dL from baseline, or the reduction of estimated glomerular filtration rate (MDRD-4) \>25%, within 48h after contrast administration, Within 48h after contrast administration | Secondary: Estimated Glomerular Filtration Rate (eGFR) at 24h From Baseline, Estimated glomerular filtration rate (eGFR) according to MDRD-4 at 24 hours from contrast administration (baseline), as an secondary efficacy laboratory assessment., 24 hours from contrast administration (baseline)|Estimated Glomerular Filtration Rate (eGFR) at 48h From Baseline, Estimated glomerular filtration rate (eGFR) according to MDRD-4 at 48 hours from contrast administration (baseline), as an secondary efficacy laboratory assessment., 48 hours from contrast administration (baseline)|Serum Creatinine at 24h From Baseline, Serum creatinine at 24 hours from contrast administration (baseline), as an secondary efficacy laboratory assessment., 24 hours from contrast administration (baseline)|Serum Creatinine at 48h From Baseline, Serum creatinine at 48 hours from contrast administration (baseline), as an secondary efficacy laboratory assessment., 48 hours from contrast administration (baseline)|Cystatin C at 24h From Baseline, Cystatin C at 24 hours from contrast administration (baseline), as an secondary efficacy laboratory assessment., 24 hours from contrast administration (baseline)|Cystatin C at 48h From Baseline, Cystatin C at 48 hours from contrast administration (baseline), as an secondary efficacy laboratory assessment., 48 hours from contrast administration (baseline)|Albumin-to-creatinine Ratio at 24h From Baseline, Albumin-to-creatinine ratio at 24 hours from contrast administration (baseline), as an secondary efficacy laboratory assessment., 24 hours from contrast administration (baseline)|Albumin-to-creatinine Ratio at 48h From Baseline, Albumin-to-creatinine ratio at 48 hours from contrast administration (baseline), as an secondary efficacy laboratory assessment., 48 hours from contrast administration (baseline)|Urea at 24h From Baseline, Urea at 24 hours from contrast administration (baseline), as an secondary efficacy laboratory assessment., 24 hours from contrast administration (baseline)|Urea at 48h From Baseline, Urea at 48 hours from contrast administration (baseline), as an secondary efficacy laboratory assessment., 48 hours from contrast administration (baseline)|Serum Sodium at 24h From Baseline, Serum sodium at 24 hours from contrast administration (baseline), as an secondary efficacy laboratory assessment., 24 hours from contrast administration (baseline)|Serum Sodium at 48h From Baseline, Serum sodium at 48 hours from contrast administration (baseline), as an secondary efficacy laboratory assessment., 48 hours from contrast administration (baseline)|Serum Potassium at 24h From Baseline, Serum potassium at 24 hours from contrast administration (baseline), as an secondary efficacy laboratory assessment., 24 hours from contrast administration (baseline)|Serum Potassium at 48h From Baseline, Serum potassium at 48 hours from contrast administration (baseline), as an secondary efficacy laboratory assessment., 48 hours from contrast administration (baseline)
|
